HIV/AIDS Osteonecrosis: Osteonecrosis is a complication of HIV infection and HAART

AIDSWEEKLY Plus; Monday, October 30, 2006
Staff Medical Writers

According to a recently published report from France, "Osteonecrosis was increasingly associated with HIV infection in the 1990s. It is unclear whether its risk increases with the duration of HIV infection, the duration of combination antiretroviral therapy (cART) or both.

"To analyze factors associated with the rate of symptomatic osteonecrosis, particularly the relative impacts of the duration of HIV infection and the duration of cART, using the French Hospital Database on HIV, which comprises a large number of subjects with substantial follow-up," a study was conducted.

"Poisson regression model was used to identify factors associated with the rate of osteonecrosis among patients enrolled in 1996-2002. The study involved 56,393 subjects with a total follow-up of 229,031 person-years. Symptomatic osteonecrosis was diagnosed in 104 subjects with an incidence rate of 4.5/10,000 person-years," investigators reported.

"Multivariate analysis identified three factors associated with the rate of osteonecrosis: prior AIDS-defining illnesses [adjusted relative rate (RR), 3.1; 95% confidence interval (CI), 2.0-4.9], the CD4 cell nadir [RR, 1.6 (95% CI, 0.9-2.9)] for CD4 cell count 50-199 cells/mcL; RR, 1.8 (95% CI, 1.0-3.3) for CD4 cell count <50 cells/mcL; both relative to CD4 cell count >200 cells/mcL and exposure to cART," wrote M. Mary-Krause and colleagues at INSERM, U720 in Paris.

"Compared with unexposed patients," continued the authors, "the RR of osteonecrosis ranged from 2.6 (95% CI, 1.2-5.9) in patients treated with cART for <12 months to 5.1 (95% CI, 2.1-12.6) in patients treated for >60 months."

Researchers concluded, "Osteonecrosis appears to be a complication of both HIV infection and cART."

Mary-Krause and colleagues published their study in AIDS (Risk factors for osteonecrosis in HIV-infected patients: impact of treatment with combination antiretroviral therapy. AIDS. 2006 Aug 1;20(12):1627-35).

For more information, contact M. Mary-Krause, INSERM, U720, 56 Blvd. Vincent Auriol, BP 335, F-75625 Paris 13, France.

Publisher contact information for the journal AIDS is: Lippincott Williams & Wilkins, 530 Walnut St., Philadelphia, PA 19106-3621, USA.

Keywords: Paris, France, HIV/AIDS, HAART, Osteonecrosis.

This article was prepared by AIDS Weekly editors from staff and other reports.

Reference

Mary-Krause M, Billaud E, Poizot-Martin I, et al., “Risk factors for osteonecrosis in HIV-infected patients: impact of treatment with combination antiretroviral therapy”, AIDS. 2006 Aug 1;20(12):1627-35.

PubMED Related articles Search

2006-10-30
AW061014

Copyright © 2006 - Charles Henderson, Publisher. All rights Reserved. Permission to reproduce granted to AEGIS by Charles W. Henderson. Authorization to reproduce for personal use granted granted by C. W. Henderson, Publisher, provided that the fee of US$4.50 per copy, per page is paid directly to the Copyright Clearance Center, 27 Congress Street, Salem, Massachusetts 01970, USA. Published by Charles Henderson, Publisher. Editorial & Publishing Office: P.O. Box 5528, Atlanta, GA 30307-0528 / Telephone: (800) 633-4931; Subscription Office: P.O. Box 830409, Birmingham, AL 35283-0409 / FAX: (205) 995-1588 http://www.newsrx.net

AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, Elton John AIDS Foundation, Bridgestone/Firestone Charitable Trust, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2006. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright © 1980,2006. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.